Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)
The purpose of this RFA is to support early clinical trials consortia poised to efficiently evaluate the biologic effects of cancer preventive agents and to determine clinically-relevant correlates in order to advance their development for cancer prevention.
The program objectives are:
To efficiently
design and conduct early phase clinical trials to assess the cancer preventive potential of NCI-sponsored agents of varying classes, many of which target molecules or processes known to be important during carcinogenesis.
These trials include phase 0 (microdosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials.
To characterize the effects of these agents on the molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlate these effects with clinical endpoints.
To develop further scientific insights into the mechanism of cancer prevention by the agent examined and continue to develop novel potential markers as determinants of response.
The program objectives are:
To efficiently
design and conduct early phase clinical trials to assess the cancer preventive potential of NCI-sponsored agents of varying classes, many of which target molecules or processes known to be important during carcinogenesis.
These trials include phase 0 (microdosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials.
To characterize the effects of these agents on the molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlate these effects with clinical endpoints.
To develop further scientific insights into the mechanism of cancer prevention by the agent examined and continue to develop novel potential markers as determinants of response.
Related Programs
Department of Health and Human Services
Cancer Cause and Prevention Research
Department of Health and Human ServicesDepartment of Health and Human Services
Agency: Department of Health and Human Services
Office: National Institutes of Health
Estimated Funding: $2,818,793
Office: National Institutes of Health
Estimated Funding: $2,818,793
Who's Eligible
Relevant Nonprofit Program Categories
Obtain Full Opportunity Text:
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-18-029.html
Additional Information of Eligibility:
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs) ; U. S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U. S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
see the funding announcement for eligibility details
Full Opportunity Web Address:
http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-18-029.html
Contact:
Agency Email Description:
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Agency Email:
Date Posted:
2018-09-14
Application Due Date:
Archive Date:
2018-12-21
Social Entrepreneurship
Spotlight
Building a Million Dollar Company Where Everyone Counts
Ganesh Natarajan is the Founder and Chairman of 5FWorld, a new platform for funding and developing start-ups, social enterprises and the skills eco-system in India. In the past two decades, he has built two of India’s high-growth software services companies – Aptech and Zensar – almost from scratch to global success.
Learn How to Identify and Avoid Grant Scams
